Registered title, quoted from ClinicalTrials.gov
JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
An open trial on B-cell acute lymphoblastic leukaemia, registered on ClinicalTrials.gov. Led by Affiliated Hospital of Guangdong Medical University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06940960, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
12 years to 75 years; sex: all
Registered eligibility fields
Refractory B-ALL: those who did not achieve complete remission after 2 courses of standard induction regimen chemotherapy, or those who did not achieve complete remission after first-line or multi-line salvage chemotherapy;
Inclusion criterion 5
Relapsed B-ALL: relapse within 12 months after first remission, or relapse after first-line / multi-line salvage chemotherapy;
Inclusion criterion 6
In addition, patients with Philadelphia chromosome positive (Ph +) should be relapsed after at least two tyrosine kinase inhibitors (TKI) treatment, or they could not tolerate TKI therapy, or have a t315i mutation, resistant to TKI drugs.
Inclusion criterion 8
Subjects who have received other study drugs within 30 days before screening, or are still in the washout period;
Exclusion criterion 3
Patients who have previously received any anti-CD19 / anti-Cluster of Differentiation 3(CD3) therapy or any other anti-CD19 therapy (except for those with normal T cell numbers and function and with CD19-positive tumors);
Exclusion criterion 4
Patients who have been previously treated with any gene therapy product, including Chimeric Antigen Receptor T(CAR-T) therapy (except patients who do not have CAR-T cells in vivo and have normal T cell number and function and are with CD19 positive tumors);
Exclusion criterion 5
Carcinoma in situ of cervical cancer or breast cancer, after curative treatment, showed no signs of recurrence for at least 3 years before the study;
Exclusion criterion 12
Baseline Eastern Cooperative Oncology Group(ECOG) score was 0-1;
Inclusion criterion 13
Glutamic aminotransferase (ALT) ≤3 times upper limit of normal (ULN);
Inclusion criterion 15
Grass aminotransferase (AST) ≤3 times ULN;
Inclusion criterion 16
Total bilirubin ≤1.5 times ULN;
Inclusion criterion 17
Serum creatinine ≤ 1.5 times ULN, or creatinine clearance ≥ 60 mL/min;
Inclusion criterion 18
Absolute neutrophil count (ANC)>1.000 / mm3;
Inclusion criterion 23
Platelet≥50.000/mm3;
Inclusion criterion 25
Hemoglobin>8.0 g/dl;
Inclusion criterion 26
At least one measurable lesion was imaging for relapsed or refractory B cell lymphoma, long diameter of> 15mm, or extranodal lesion of> 10mm, along with a positive Positron Emission Tomography - Computed Tomography(PET-CT) examination.
Inclusion criterion 11
Subjects with active hepatitis B (defined as Hepatitis B Virus(HBV) DNA test value> 500 IU / mL) or hepatitis C (HCV RNA positive); subjects with HIV positive or treponema pallidum positive;
Exclusion criterion 7
The primary malignancy has been completely removed and is in complete remission for 5 years.
Exclusion criterion 13
Female subjects in pregnant or lactating, or women with planned pregnancy within 2 years after JY231 infusion or male partner with planned pregnancy within 2 years after JY231 infusion;
Exclusion criterion 17
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06940960, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Subject voluntarily sign informed consent and are willing and able to comply with all trial requirements;
- Age is 12-75 years old and gender is not limited;
- Malignancy cells in bone marrow or peripheral blood are Cluster of Differentiation 19 - positive(CD19+) detected by flow cytometric analysis;
- Meet the clinical criteria for relapsed or refractory B-cell lymphoma, including: indolent lymphoma (iNHL), such as follicular lymphoma (FL) and marginal zone lymphoma (MZL); aggressive B-cell lymphoma, like diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), and T-rich lymphocyte-bearing large B-cell lymphoma (TCRBCL), or have a diagnosis of acute B-lymphocytic leukemia (B-ALL) and meet one of the following conditions:
- Refractory B-ALL: those who did not achieve complete remission after 2 courses of standard induction regimen chemotherapy, or those who did not achieve complete remission after first-line or multi-line salvage chemotherapy;
- Relapsed B-ALL: relapse within 12 months after first remission, or relapse after first-line / multi-line salvage chemotherapy;
- Relapse after autologous or allogeneic hematopoietic stem cell transplantation;
- In addition, patients with Philadelphia chromosome positive (Ph +) should be relapsed after at least two tyrosine kinase inhibitors (TKI) treatment, or they could not tolerate TKI therapy, or have a t315i mutation, resistant to TKI drugs.
- Morphological examination of bone marrow cells showed the proportion of primitive and naive lymphocytes was> 5%;
- No Hematopoietic Stem Cell Transplantation(HSCT) within 6 months before enrollment;
- At least one measurable lesion was imaging for relapsed or refractory B cell lymphoma, long diameter of> 15mm, or extranodal lesion of> 10mm, along with a positive Positron Emission Tomography - Computed Tomography(PET-CT) examination.
- More than 12 weeks of expected survival period
- Baseline Eastern Cooperative Oncology Group(ECOG) score was 0-1;
- Adequate organ function (criteria regarding liver and kidney function can be moderately relaxed):
- Glutamic aminotransferase (ALT) ≤3 times upper limit of normal (ULN);
- Grass aminotransferase (AST) ≤3 times ULN;
- Total bilirubin ≤1.5 times ULN;
- Serum creatinine ≤ 1.5 times ULN, or creatinine clearance ≥ 60 mL/min;
- Indoor oxygen saturation ≥ 92%;
- Left ventricular ejection fraction (LVEF)≥55%, echocardiography confirmed no pericardial effusion and no clinically significant ECG findings;
- There is no clinically significant pleural effusion;
- Adequate bone marrow reserve without transfusion, defined as:
- Absolute neutrophil count (ANC)>1.000 / mm3;
- Absolute lymphocyte count (ALC)≥ 300 / mm3;
- Platelet≥50.000/mm3;
- Hemoglobin>8.0 g/dl;
- Subjects using the following drugs need to meet the following conditions:
- Steroids: The therapeutic dose of steroids must be stopped 72 hours before JY231 infusion. However, physiological alternative doses of steroids are allowed;
- Immunosuppression: Any immunosuppressive drug must be stopped at ≥4 weeks prior to enrollment;
- Antiproliferative therapy other than lymphodepletion chemotherapy within two weeks of infusion;
- Cluster of Differentiation 20(CD20) antibody-related therapy must be stopped within 4 weeks before infusion or 5 half-lives after the CD20 antibody;
- CNS disease prophylaxis must be stopped 1 week before JY231 infusion (e. g. intrathecal methotrexate).
- Reproductive men, sexual partners ensure effective contraception; fertile women, adopted effective contraception and agreed to use contraception throughout the study period.
Exclusion Criteria:
- Subjects with active cerebrospinal fluid malignant cells or brain metastases, or subjects with active central nervous system (CNS) lymphoma, or CNS leukaemia;
- Subjects with a history of active CNS disease, such as seizures, cerebrovascular ischemia / hemorrhage, dementia, cerebellar disease, or any autoimmune disease associated with CNS involvement;
- Subjects who have received other study drugs within 30 days before screening, or are still in the washout period;
- Patients who have previously received any anti-CD19 / anti-Cluster of Differentiation 3(CD3) therapy or any other anti-CD19 therapy (except for those with normal T cell numbers and function and with CD19-positive tumors);
- Patients who have been previously treated with any gene therapy product, including Chimeric Antigen Receptor T(CAR-T) therapy (except patients who do not have CAR-T cells in vivo and have normal T cell number and function and are with CD19 positive tumors);
- Subjects with radiation therapy within 2 weeks prior to the infusion;
- Subjects with active hepatitis B (defined as Hepatitis B Virus(HBV) DNA test value> 500 IU / mL) or hepatitis C (HCV RNA positive); subjects with HIV positive or treponema pallidum positive;
- Subjects with uncontrolled acute life-threatening bacterial, viral, or fungal infection (e. g. positive blood culture 72 hours before infusion);
- Subjects with unstable angina pectoris and / or myocardial infarction within the 6 months prior to screening;
- Subjects with concurrent or previously diagnosed with other malignancies, except for the patients under following conditions:
- Well treated basal cells, papillary thyroid carcinoma, squamous cell carcinoma (adequate wound healing is required before enrollment into this study);
- Carcinoma in situ of cervical cancer or breast cancer, after curative treatment, showed no signs of recurrence for at least 3 years before the study;
- The primary malignancy has been completely removed and is in complete remission for 5 years.
- Arrhythmic subjects without medical management control;
- Subjects receiving oral anticoagulation within 1 week before JY231 injection infusion;
- Having active neurological autoimmune or inflammatory conditions (such as Guillain-Barre syndrome, amyotrophic lateral sclerosis);
- Female subjects in pregnant or lactating, or women with planned pregnancy within 2 years after JY231 infusion or male partner with planned pregnancy within 2 years after JY231 infusion;
- Subjects with taboo study procedures or other medical conditions that may put them at unacceptable risk according to the investigator's judgment and / or clinical criteria.
- Other conditions that the investigator believes that the subjects should not be enrolled in this clinical trial, such as poor compliance.
Quoted from ClinicalTrials.gov, NCT06940960, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06940960, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.